The CEO of Novo Nordisk, Lars Fruergaard Jørgensen, stood before analysts in early 2025 and delivered a confession that rattled the market. 'Lilly has been more successful in gaining market share,' he said, before pivoting to a defensive claim: his company's oral Wegovy had generated over 5 million prescriptions in six months, making it one of the fastest-selling drugs in pharmaceutical history. The stock dropped 6% that day. Investors were not buying the math.
This is not a crypto project, but the dynamics are identical. A dominant protocol faces a fork with better tokenomics. A community leader admits the competitor is winning. The native token price declines despite a bullish narrative. As an on-chain detective who has audited over 40 DeFi protocols, I recognize the pattern: the market is pricing in a structural risk that the data does not yet confirm, but the trends are undeniable.
Context: The GLP-1 Duopoly and the Oral Pivot
The GLP-1 receptor agonist market for weight loss has been a two-player game since 2021. Novo Nordisk's semaglutide (Wegovy, Ozempic) and Eli Lilly's tirzepatide (Zepbound, Mounjaro) dominate a category projected to reach $100–150 billion by 2030. The competition has shifted from injectable to oral formulations. Novo's oral semaglutide (Rybelsus for diabetes, oral Wegovy for weight loss) uses a proprietary SNAC absorption enhancement technology to deliver a peptide orally. Lilly's answer is orforglipron, a non-peptide small-molecule GLP-1 agonist that can be manufactured at lower cost without cold-chain logistics.
Novo's oral Wegovy launched in January 2025 and reportedly achieved 5 million prescriptions within six months. The CEO cited this as proof that the company's 'price reduction for volume' strategy is working. But the numbers demand forensic scrutiny. The 5 million figure comes from an internal source, not independently audited by IQVIA or a third-party prescription tracker. In my experience auditing DeFi projects, unaudited TVL claims are often inflated by 30–50% due to double-counting or wash trading. The same skepticism applies here.
Core: Systematic Teardown of the Competitive Dynamics
Let me break down the four key dimensions that the market is pricing into Novo's stock, but which the CEO's narrative obscures.
1. The Efficacy Data Trap
Novo's CEO claimed that its oral pill achieves 17% weight loss versus Lilly's 12% in a similar trial. This is a classic indirect comparison trap. The two trials have different patient baselines, background lifestyle interventions, and dosing regimens. Lilly's Zepbound (tirzepatide) has demonstrated 20%+ weight loss in the SURMOUNT-1 trial at 72 weeks. The 12% figure likely refers to a lower-dose cohort or a shorter duration. Without a head-to-head trial, the 17% is a marketing artifact, not a clinical fact. Data does not negotiate; it only reveals. And the data reveals that tirzepatide has superior efficacy in every properly controlled study.
2. The Oral Window Is Narrowing
Novo's oral semaglutide is a first-mover advantage in the oral GLP-1 space, but it is a peptide-based formulation, which requires the SNAC technology. Lilly's orforglipron is a small molecule, which can be produced at a fraction of the cost and does not require refrigeration. Orforglipron is in Phase III trials and could reach the market by 2026–2027. Once approved, it will undercut oral Wegovy on price and scale. Historically, small-molecule drugs have captured 60–80% of oral markets within three years of launch when competing against peptide-based oral drugs. The window for Novo to capture switching costs is two to three years at most.
3. The Concentration Risk That Nobody Talks About
Novo Nordisk derives approximately 90% of its revenue from GLP-1 products. Eli Lilly is around 60%. This lopsided dependency means that a 10% price cut on GLP-1 drugs reduces Novo's operating profit by roughly 15–20% (assuming 50% contribution margin), while Lilly's impact is half that. The IRA (Inflation Reduction Act) is about to allow Medicare to negotiate drug prices directly. Ozempic and Mounjaro are top candidates for the next round of negotiations, likely starting in 2026. A 30–50% price cut on Medicare sales would devastate Novo's margin structure. The market is discounting this risk, and rightfully so.
4. The Prescription Data Mirage
I have analyzed on-chain data from over 50 DeFi projects that claimed 'user growth' but were actually sybil attacks. The 5 million oral Wegovy prescriptions in six months is an extraordinary claim that requires extraordinary evidence. The average injectable Wegovy patient costs about $1,350 per month in the US. Assuming insurance coverage and discounts, net revenue per prescription is around $600–800. Five million prescriptions would imply $3–4 billion in annualized revenue. But the total US addressable market for GLP-1 weight loss drugs in 2024 was about $25 billion. Novo already holds a 55–60% share. To generate 5 million new prescriptions in six months, Novo would need to capture nearly a third of the entire market's new patient flow. The numbers do not add up without verification. My suspicion is that the 5 million figure includes refills, not just new patients, and may also include the Rybelsus (diabetes) overlap. The data does not negotiate.
Contrarian: What the Bulls Got Right
Despite my skepticism, the bulls have a point on three fronts. First, the novelty of an oral GLP-1 pill is real. Injectable obesity drugs have a 15–20% dropout rate due to needle phobia and injection site reactions. Oral administration could expand the patient pool by 5–10 percentage points, which translates to tens of millions of patients globally. Second, Novo's SNAC technology is a patent-protected platform that extends beyond semaglutide. It can be applied to other peptide drugs, providing a pipeline of future oral formulations. Third, the cardiovascular outcomes trial SELECT demonstrated that semaglutide reduces major adverse cardiac events by 20% independent of weight loss. This label expansion transforms Wegovy from a 'cosmetic weight loss' drug to a 'chronic cardiometabolic therapy' that is more likely to be covered by Medicare. If CMS changes its rule to cover obesity drugs for Medicare beneficiaries, the market could double overnight.
However, these positives are already priced into Novo's stock at 25–30x P/E. The discount to Lilly's 50–60x P/E is not an inefficiency; it is a rational reflection of the risk that Lilly's small-molecule oral will destroy Novo's oral advantage within three years, and that IRA price cuts will compress margins. The market is not ignoring the data; it is interpreting the data through a probabilistic lens.
Takeaway: The Verdict from a Cold Dissector
Novo Nordisk is not a failing company. It has a dominant product, a strong pipeline, and a first-mover advantage in oral GLP-1. But the market is correct to price in a discount for the structural threats: the IRA, Lilly's small-molecule, and the concentration risk. The 5 million prescription claim is a piece of data that needs independent verification before it can be used to justify a re-rating. As I tell my clients in crypto audits: trust the code, not the community. Here, trust the prescription data, not the CEO. Data does not negotiate; it only reveals. And what it reveals is a market that is already shifting the balance of power. The next 18 months will determine whether Novo can defend its position or if it will be the Blockbuster to Lilly's Netflix.